AIMS: CCND1 and EMSY, on 11q13, are frequently amplified in breast cancer. CCND1 is implicated in cell cycle progression and EMSY is a BRCA2-associated repressor protein. The aim was to investigate gene copy numbers of CCND1 and EMSY and to determine if CCND1 amplification is associated with reduced survival of tamoxifen-treated breast cancer patients. METHODS AND RESULTS: Fluorescence in situ hybridization (FISH) was performed on 111 consecutive and 354 oestrogen receptor (ER)+ tamoxifen-treated breast cancers. In the consecutive set, CCND1 and EMSY were amplified in 14.8% and 7.2%, respectively, and deleted in 8.7% and 13.5%, respectively. In the ER+ set, CCND1 and EMSY were amplified in 20.6% and 9.6%, respectively, and deleted in 1.7% and 4.2%, respectively. CCND1 and EMSY gene amplifications were associated with decreased overall survival (OS) (P = 0.03 and P = 0.04, respectively) of patients in the ER+ set. CONCLUSION: As hypothesized, CCND1 amplifications are associated with poor OS in ER+ patients. EMSY amplification is also associated with poor OS. However, as >70% of EMSY amplifications were CCND1 amplified, EMSY may not have any additional effect on survival of ER+ breast cancer.
AIMS: CCND1 and EMSY, on 11q13, are frequently amplified in breast cancer. CCND1 is implicated in cell cycle progression and EMSY is a BRCA2-associated repressor protein. The aim was to investigate gene copy numbers of CCND1 and EMSY and to determine if CCND1 amplification is associated with reduced survival of tamoxifen-treated breast cancerpatients. METHODS AND RESULTS: Fluorescence in situ hybridization (FISH) was performed on 111 consecutive and 354 oestrogen receptor (ER)+ tamoxifen-treated breast cancers. In the consecutive set, CCND1 and EMSY were amplified in 14.8% and 7.2%, respectively, and deleted in 8.7% and 13.5%, respectively. In the ER+ set, CCND1 and EMSY were amplified in 20.6% and 9.6%, respectively, and deleted in 1.7% and 4.2%, respectively. CCND1 and EMSY gene amplifications were associated with decreased overall survival (OS) (P = 0.03 and P = 0.04, respectively) of patients in the ER+ set. CONCLUSION: As hypothesized, CCND1 amplifications are associated with poor OS in ER+ patients. EMSY amplification is also associated with poor OS. However, as >70% of EMSY amplifications were CCND1 amplified, EMSY may not have any additional effect on survival of ER+ breast cancer.
Authors: Anoek H J Verschuur-Maes; Cathy B Moelans; Peter C de Bruin; Paul J van Diest Journal: Cell Oncol (Dordr) Date: 2014-04-02 Impact factor: 6.730
Authors: Konstantin J Dedes; Paul M Wilkerson; Daniel Wetterskog; Britta Weigelt; Alan Ashworth; Jorge S Reis-Filho Journal: Cell Cycle Date: 2011-04-15 Impact factor: 4.534
Authors: Robert Kornegoor; Cathy B Moelans; Anoek H J Verschuur-Maes; Marieke C H Hogenes; Peter C de Bruin; Joost J Oudejans; Luigi Marchionni; Paul J van Diest Journal: Breast Cancer Res Treat Date: 2012-04-13 Impact factor: 4.872
Authors: Cathy B Moelans; Roel A de Wegers; Hanneke N Monsuurs; Anoek H J Maess; Paul J van Diest Journal: Cell Oncol (Dordr) Date: 2011-05-06 Impact factor: 6.730
Authors: Kirsi M Määttä; Riikka Nurminen; Minna Kankuri-Tammilehto; Anne Kallioniemi; Satu-Leena Laasanen; Johanna Schleutker Journal: BMC Cancer Date: 2017-07-24 Impact factor: 4.430
Authors: Robert L Hollis; Michael Churchman; Caroline O Michie; Tzyvia Rye; Laura Knight; Andrena McCavigan; Timothy Perren; Alistair R W Williams; W Glenn McCluggage; Richard S Kaplan; Gordon C Jayson; Amit Oza; D Paul Harkin; C Simon Herrington; Richard Kennedy; Charlie Gourley Journal: Cancer Date: 2019-06-02 Impact factor: 6.860